Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
COGT Stock Summary
In the News

3 Lost Formula Stocks to Consider for the 2nd Half of 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

These Are the Top 10 Holdings of David Kim
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors
Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found in patients with advanced and/or treatment-resistant GIST.

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now
Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.

Cogent Biosciences: What's Ahead
Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs.

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Cogent (COGT) Surges on Robust Data from Mastocytosis Study
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
COGT Financial details
COGT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.56 | 2.95 | 0.71 | 0 | 0 | |
Net income per share | -5.55 | -3.97 | -6 | -1.64 | -2.26 | |
Operating cash flow per share | -5.22 | -5.45 | -3.24 | -1.34 | -2.02 | |
Free cash flow per share | -5.31 | -5.45 | -3.24 | -1.38 | -2.14 | |
Cash per share | 12.63 | 4.91 | 21.86 | 5.01 | 4.41 | |
Book value per share | 9.68 | 4.17 | 21.18 | 4.89 | 4.35 | |
Tangible book value per share | 9.68 | 4.17 | 21.18 | 4.89 | 4.35 | |
Share holders equity per share | 9.68 | 4.17 | 21.18 | 4.89 | 4.35 | |
Interest debt per share | 0.61 | 0.79 | 0.47 | 0.07 | 0.4 | |
Market cap | 109.54M | 21.95M | 124.44M | 375.85M | 679.03M | |
Enterprise value | 53.87M | -9.45M | -112.54M | 159.33M | 558.79M | |
P/E ratio | -3.17 | -0.72 | -1.87 | -5.23 | -5.12 | |
Price to sales ratio | 11.25 | 0.98 | 15.81 | 0 | 0 | |
POCF ratio | -3.37 | -0.53 | -3.47 | -6.4 | -5.72 | |
PFCF ratio | -3.32 | -0.53 | -3.47 | -6.21 | -5.41 | |
P/B Ratio | 1.82 | 0.69 | 0.53 | 1.75 | 2.66 | |
PTB ratio | 1.82 | 0.69 | 0.53 | 1.75 | 2.66 | |
EV to sales | 5.53 | -0.42 | -14.3 | 0 | 0 | |
Enterprise value over EBITDA | -1.55 | 0.29 | 1.25 | -2.11 | -3.78 | |
EV to operating cash flow | -1.66 | 0.23 | 3.14 | -2.71 | -4.71 | |
EV to free cash flow | -1.63 | 0.23 | 3.14 | -2.63 | -4.45 | |
Earnings yield | -0.32 | -1.38 | -0.53 | -0.19 | -0.2 | |
Free cash flow yield | -0.3 | -1.89 | -0.29 | -0.16 | -0.18 | |
Debt to equity | 0.06 | 0.19 | 0.02 | 0.01 | 0.08 | |
Debt to assets | 0.04 | 0.12 | 0.02 | 0.01 | 0.07 | |
Net debt to EBITDA | 1.61 | 0.98 | 2.64 | 2.87 | 0.81 | |
Current ratio | 3.25 | 3.06 | 18.7 | 13.04 | 9.87 | |
Interest coverage | 0 | 0 | 0 | 0 | -37.06 | |
Income quality | 0.94 | 1.3 | 0.48 | 0.81 | 0.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.77 | 0.49 | 2.21 | 0 | 0 | |
Research and developement to revenue | 3.93 | 1.94 | 9.23 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0 | 0 | 0.03 | 0.06 | |
Capex to revenue | -0.06 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.42 | -0.03 | 0 | -11.69 | -1.17 | |
Stock based compensation to revenue | 0.32 | 0.14 | 0.76 | 0 | 0 | |
Graham number | 34.76 | 19.3 | 53.45 | 13.43 | 14.87 | |
ROIC | -0.59 | -0.7 | -0.3 | -0.34 | -0.47 | |
Return on tangible assets | -0.4 | -0.61 | -0.26 | -0.31 | -0.44 | |
Graham Net | 8.7 | 2.79 | 20.39 | 4.61 | 3.65 | |
Working capital | 56.06M | 27.34M | 231.82M | 205.56M | 238.12M | |
Tangible asset value | 60.23M | 31.76M | 234.67M | 214.18M | 255.74M | |
Net current asset value | 55.31M | 22.93M | 228.66M | 204.73M | 219.89M | |
Invested capital | 0.06 | 0.19 | 0.02 | 0.01 | 0.08 | |
Average receivables | 1.25M | 1.83M | 1000K | 0 | 0 | |
Average payables | 1.43M | 2.35M | 1.96M | 2.11M | 4.66M | |
Average inventory | 37.5K | 0 | 0 | 0 | 0 | |
Days sales outstanding | 62.55 | 32.45 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 5.84 | 11.25 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.57 | -0.95 | -0.28 | -0.34 | -0.52 | |
Capex per share | -0.09 | 0 | 0 | -0.04 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.48 | -0.5 | -0.48 | -0.59 | -0.64 | |
Operating cash flow per share | -0.49 | -0.42 | -0.56 | -0.43 | 0 | |
Free cash flow per share | -0.54 | -0.45 | -0.57 | -0.45 | 0 | |
Cash per share | 4.16 | 3.68 | 3.11 | 4.41 | 3.24 | |
Book value per share | 4.17 | 3.63 | 3.16 | 4.66 | 3.52 | |
Tangible book value per share | 4.17 | 3.63 | 3.16 | 4.66 | 3.52 | |
Share holders equity per share | 4.17 | 3.63 | 3.16 | 4.66 | 3.52 | |
Interest debt per share | 0.31 | 0.31 | 0.21 | 0.26 | 0.22 | |
Market cap | 1.04B | 814.86M | 763.23M | 885.08M | 840.12M | |
Enterprise value | 917.59M | 694.62M | 621.99M | 690.12M | 772.48M | |
P/E ratio | -7.79 | -5.74 | -5.62 | -5.02 | -3.79 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -30.14 | -27.71 | -19.31 | -27.6 | 0 | |
PFCF ratio | -27.5 | -25.97 | -18.79 | -26.56 | 0 | |
P/B Ratio | 3.58 | 3.19 | 3.41 | 2.54 | 2.77 | |
PTB ratio | 3.58 | 3.19 | 3.41 | 2.54 | 2.77 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -27.71 | -15.88 | -14.63 | -14.66 | -12.97 | |
EV to operating cash flow | -26.64 | -23.62 | -15.74 | -21.52 | 0 | |
EV to free cash flow | -24.31 | -22.14 | -15.31 | -20.71 | 0 | |
Earnings yield | -0.03 | -0.04 | -0.04 | -0.05 | -0.07 | |
Free cash flow yield | -0.04 | -0.04 | -0.05 | -0.04 | 0 | |
Debt to equity | 0.07 | 0.08 | 0.09 | 0.06 | 0.06 | |
Debt to assets | 0.06 | 0.07 | 0.07 | 0.05 | 0.05 | |
Net debt to EBITDA | 3.64 | 2.75 | 3.32 | 4.14 | 1.14 | |
Current ratio | 12.59 | 9.87 | 10.71 | 12.99 | 9.01 | |
Interest coverage | -24.55 | -20.73 | 9.3 | 0 | 0 | |
Income quality | 0.98 | 0.74 | 1.02 | 0.73 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.1 | 0.07 | 0.03 | 0.04 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.89 | -2.1 | -1.53 | -1.03 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.7 | 6.41 | 5.84 | 7.86 | 7.13 | |
ROIC | -0.11 | -0.13 | -0.14 | -0.11 | -0.17 | |
Return on tangible assets | -0.1 | -0.12 | -0.13 | -0.11 | -0.16 | |
Graham Net | 3.56 | 3.04 | 2.55 | 3.82 | 2.63 | |
Working capital | 272.87M | 238.12M | 205.15M | 308.76M | 278.12M | |
Tangible asset value | 289.94M | 255.74M | 223.56M | 348.43M | 302.9M | |
Net current asset value | 254.8M | 219.89M | 186.64M | 290.58M | 260.29M | |
Invested capital | 0.07 | 0.08 | 0.09 | 0.06 | 0.06 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.79M | 4.97M | 5.01M | 5.67M | 8.51M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.14 | -0.15 | -0.13 | -0.18 | |
Capex per share | -0.05 | -0.03 | -0.02 | -0.02 | 0 |
COGT Frequently Asked Questions
What is Cogent Biosciences, Inc. stock symbol ?
Cogent Biosciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol COGT
Is Cogent Biosciences, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $20.33. The lowest prediction is $15 and the highest is $24
What is COGT stock prediction ?
What is Cogent Biosciences, Inc. stock quote today ?
Cogent Biosciences, Inc. stock price is $8.64 today.
Is Cogent Biosciences, Inc. stock public?
Yes, Cogent Biosciences, Inc. is a publicly traded company.